Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

AI Briefing

• – Zai Lab receives FDA Fast Track Designation for Zoci, a DLL3-targeting ADC for epNECs treatment.
• – Zoci is a potential first-in-class ADC for epNECs after standard first-line therapy.
• – Zai Lab's Zoci has received Fast Track Designation for the treatment of extrapulmonary neuroendocrine carcinomas (epNECs).